The availability of cell-internalizing aptamers that target cancer cell antigens, such as HER2 [22], EGFRvIII [50], and nucleolin [51,52], has enabled the development of various aptamer-based therapeutic agents for targeted oligonucleotide delivery. This evidence concerns the gene ERBB2 and cancer.